The present invention relates to methods and compositions for treating subterranean formations, and more specifically, to acid-generating fluid loss control additives that are useful in petroleum recovery operations including fracturing.
Providing effective fluid-loss control for well treatment fluids is highly desirable. A “treatment fluid” is a fluid used in a subterranean application for any purpose. The term “treatment” as used herein does not imply any particular action by the fluid or any component thereof. Fluid-loss control materials are often added to treatment fluids to aid in fluid loss control. These are additives that are generally designed to lower the volume of a filtrate that passes through a filter medium, e.g., permeable rock or a filter cake. Most attain their fluid-loss control from the presence of solvent-specific solids, or from polymers that rely on filter cake buildup and on viscoelasticity to inhibit flow into and through the formation. A variety of fluid-loss control materials have been used and evaluated, including foams, oil-soluble resins, acid-soluble particulates, graded salt slurries, linear viscoelastic polymers, and heavy metal-crosslinked polymers. Their respective comparative effects are well documented.
Another technique that has been developed to control fluid loss includes the addition of a hydrocarbon-based fluid (also referred to generically as an “oil”) to the treatment fluid in small droplets. The droplets are dispersed within the treatment fluid in an amount usually around about 1% to 5% by volume. Diesel is a common example. Other light hydrocarbons have been used as well. The droplets of the hydrocarbon-based fluid are thought to reduce the permeability of the polymer build-up in the filter cake. The oil droplets are thought to occupy space in the filter cake, but do not go into the rock to plug pore throats therein. The addition of approximately 2% to about 5% of an oil to a treatment fluid can lead to significant decreases in the amount of leak off of the treatment fluid.
The present invention relates to methods and compositions for treating subterranean formations, and more specifically, to acid-generating fluid loss control additives that are useful in petroleum recovery operations including fracturing.
In one embodiment, the present invention provides a method of providing fluid loss control comprising: providing a treatment fluid; adding to the treatment fluid an acid-generating fluid loss control additive comprising an acid-generating component wherein the acid-generating fluid loss control additive forms droplets in the treatment fluid; and placing the treatment fluid into a subterranean formation.
In another embodiment, the present invention provides a method of comprising: providing a fracturing fluid that comprises an aqueous base fluid, a gelling agent, proppant particulates, and at least a plurality of droplets of acid-generating fluid loss control additives; and placing the fracturing fluid into a subterranean formation at a pressure sufficient to create or enhance a fracture therein.
In another embodiment, the present invention provides a method of degrading a filter cake comprising: providing a treatment fluid that comprises an aqueous base fluid and at least a plurality of droplets of acid-generating fluid loss control additives; placing the treatment fluid into a subterranean formation; allowing the droplets of the acid-generating fluid loss control additive to become incorporated into at least a portion of a filter cake in the subterranean formation; allowing the acid-generating fluid loss control additives to generate an acid; and allowing the acid to degrade an acid soluble degradable portion of the filter cake.
The features and advantages of the present invention will be readily apparent to those skilled in the art upon a reading of the description of the preferred embodiments, which follows.
A more complete understanding of the present disclosure and advantages thereof may be acquired by referring to the following description taken in conjunction with the accompanying drawings, wherein:
While the present invention is susceptible to various modifications and alternative forms, specific exemplary embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description herein of specific embodiments is not intended to limit or define the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims. The figures should in no way be used to limit the meaning of the claim terms.
The present invention relates to methods and compositions for treating subterranean formations, and more specifically, to acid-generating fluid loss control additives that are useful in petroleum recovery operations including fracturing.
The acid-generating fluid loss control additives of the present invention may be added to any treatment fluid in such a way that the acid-generating fluid loss control additives form droplets within the treatment fluid. The term “droplet” as used herein refers to small dispersed, discrete, substantially immiscible drops within a treatment fluid. The size of the droplets may be important for a given application, and therefore, one should take the size of the droplets into consideration when designing the treatment. In some instances, smaller droplets, e.g., less than 500 microns, may be useful, and in some instances, those that are less than 100 microns may be even more useful. Generally speaking, coalescence into larger droplets may reduce the effectiveness of the droplets as a fluid loss control additive. For instance, it may become more difficult to incorporate them into a filter cake. The droplet size may be affected by choosing appropriate surfactants, as recognized by one skilled in the art with the benefit of this disclosure.
The acid-generating fluid loss control additives of the present invention may become incorporated within a filter cake in a subterranean formation and provide fluid loss control, and later may act as a delayed breaker for the filter cake. In addition to providing fluid loss control, one of the many advantages of the present invention is that the acid-generating fluid loss control additives of the present invention is that they can assist in degrading filter cakes that are present in the subterranean formation, e.g., those that result from fracturing fluids that build filter cakes on permeable formation surfaces. This may be especially beneficial when, for example, the filter cake has a high concentration of polymer, e.g., guar. This is advantageous because if a sufficient amount of breaker to break that polymer in the filter cake is added to a treatment fluid, the fluid will prematurely break, which is undesirable. Additionally, when the droplets become incorporated in the pore throats of the formation, the droplets may go from being substantially water-immiscible to substantially water-miscible when the degrade. Before degradation, they offer resistance to flow. After degradation, they do not impede flow because they are substantially miscible in water or the treatment fluid.
The acid-generating fluid loss control additives of the present invention may be added to any treatment fluid in which it is desirable to control fluid loss. Examples include fracturing fluids, drill-in fluids, gravel pack fluids, and fluid loss control pills. Hydraulic fracturing operations are stimulation techniques that generally involve pumping a treatment fluid (e.g., a fracturing fluid) into a well bore that penetrates a subterranean formation at a sufficient hydraulic pressure to create or enhance one or more cracks, or “fractures,” in the subterranean formation. The fracturing fluid may comprise particulates, often referred to as “proppant,” that are deposited in the fractures. The proppant particulates, inter alia, prevent the fractures from fully closing upon the release of hydraulic pressure, forming conductive channels through which fluids may flow to the well bore. Once at least one fracture is created or enhanced and the proppant particulates are substantially in place, the fracturing fluid may be “broken” (i.e., the viscosity is reduced), and the fracturing fluid may be recovered from the formation. Any fracturing fluid that is suitable for use in subterranean formations may be used in conjunction with the present invention.
The acid-generating fluid loss control additives of the present invention comprise an acid-generating component. Suitable acid generating components include esters; and ortho ethers (that may be referred to as ortho esters). Poly(ortho ethers) (that may be referred to as poly(ortho esters)); aliphatic polyesters; lactides, poly(lactides); glycolides; poly(glycolides); lactones; poly(ε-caprolactones); poly(hydroxybutyrates); anhydrides; poly(anhydrides); and poly(amino acids) may also be suitable if dissolved in an appropriate solvent that does negatively impact the subterranean formation in which they be used (e.g., they do not create an additional clean up hindrance). Derivatives and combinations of these may be suitable as well. The term “derivative” is defined herein to include any compound that is made from the base compound, for example, by replacing one atom in the base compound with another atom or group of atoms. One example of a suitable combination of acid-generating components includes a blend of an ester and an ortho ether. The acid-generating component also may comprise an esterase enzyme if desired. It is within the ability of one skilled in the art, with the benefit of this disclosure, to select a suitable acid-generating component. When used in the present invention, a preferable result is achieved if the acid-releasing degradable material degrades slowly over time as opposed to instantaneously. Preferably, these fluid loss additives are added in liquid form to the treatment fluid to form droplets within the treatment fluid.
Certain pH adjusters may be included to affect the degradation time of the acid-generating fluid loss control additives, if desired. For example, in some instances, it may be desirable to add a strong base to keep the pH relatively high at some point in the process. This may be beneficial when using an ortho ether acid-generating fluid loss control additive, for example. Any base that is suitable for use in a subterranean operation that does not adversely affect other components therein may be used. Sodium hydroxide is a suitable example. Other well-known bases may also be used.
The acid-generating fluid loss control additives of the present invention should be included in a treatment fluid in an amount sufficient to achieve the desired degree of fluid loss control. In some embodiments, this will be from about 0.1% to about 15% of the composition and in certain preferred embodiments, from about 1% to about 5% of the composition. In some embodiments, wherein emulsion properties are desired, 60% to 90% may be used.
The fluid loss control additives of the present invention may be used in conjunction with any treatment fluid in which it is desirable to control fluid loss, e.g., a fracturing fluid, etc.
The treatment fluids that may be used in conjunction with the present invention generally comprise an aqueous base fluid, a gelling agent, and sometimes a breaker. In certain embodiments, the gelling agent may comprise a “crosslinked gelling agent,” which is defined herein to mean that at least a portion of the gelling agent may be crosslinked by a crosslinking reaction comprising a crosslinking agent.
The aqueous base fluid used in the treatment fluids suitable for use with the present invention may comprise fresh water, saltwater (e.g., water containing one or more salts dissolved therein), brine, seawater, or combinations thereof. Generally, the water may be from any source, provided that it does not contain components that might adversely affect the stability and/or performance of the treatment fluids. In certain embodiments, the density of the aqueous base fluid can be increased, among other purposes, to provide additional particle transport and suspension in the treatment fluids of the present invention. In certain embodiments, the pH of the aqueous base fluid may be adjusted (e.g., by a buffer or other pH adjusting agent), among other purposes, to activate a crosslinking agent, and/or to reduce the viscosity of the treatment fluid (e.g., activate a breaker, deactivate a crosslinking agent). In these embodiments, the pH may be adjusted to a specific level, which may depend on, among other factors, the types of gelling agents, crosslinking agents, and/or breakers included in the treatment fluid. One of ordinary skill in the art, with the benefit of this disclosure, will recognize when such density and/or pH adjustments are appropriate. One should be aware of this pH and its potential effect on the fluid loss control agents of the present invention.
The gelling agents utilized in the treatment fluids may comprise any polymeric material capable of increasing the viscosity of an aqueous fluid. In certain embodiments, the gelling agent may comprise polymers that have at least two molecules that are capable of forming a crosslink in a crosslinking reaction in the presence of a crosslinking agent, and/or polymers that have at least two molecules that are so crosslinked (i.e., a crosslinked gelling agent). The gelling agents may be naturally-occurring, synthetic, or a combination thereof. In certain embodiments, suitable gelling agents may comprise polysaccharides, and derivatives thereof that contain one or more of these monosaccharide units: galactose, mannose, glucoside, glucose, xylose, arabinose, fructose, glucuronic acid, or pyranosyl sulfate. Examples of suitable polysaccharides include, but are not limited to, guar gums (e.g., hydroxyethyl guar, hydroxypropyl guar, carboxymethyl guar, carboxymethylhydroxyethyl guar, and carboxymethylhydroxypropyl guar (“CMHPG”)), cellulose derivatives (e.g., hydroxyethyl cellulose, carboxyethylcellulose, carboxymethylcellulose, and carboxymethylhydroxyethylcellulose), xanthan, diutan, scleroglucan, succinoglycan, and combinations thereof. In certain embodiments, the gelling agents comprise an organic carboxylated polymer, such as CMHPG. In certain embodiments, the derivatized cellulose is a cellulose grafted with an allyl or a vinyl monomer, such as those disclosed in U.S. Pat. Nos. 4,982,793; 5,067,565; and 5,122,549, the relevant disclosures of which are incorporated herein by reference. Additionally, polymers and copolymers that comprise one or more functional groups (e.g., hydroxyl, cis-hydroxyl, carboxylic acids, derivatives of carboxylic acids, sulfate, sulfonate, phosphate, phosphonate, amino, or amide groups) may be used.
The gelling agent may be present in the treatment fluids in an amount sufficient to provide the desired viscosity. In some embodiments, the gelling agents may be present in an amount in the range of from about 0.12% to about 2.0% by weight of the treatment fluid. In certain embodiments, the gelling agents may be present in an amount in the range of from about 0.18% to about 0.72% by weight of the treatment fluid.
In those embodiments of the present invention wherein it is desirable to crosslink the gelling agent, the treatment fluid may comprise one or more crosslinking agents. The crosslinking agents may comprise a metal ion that is capable of crosslinking at least two molecules of the gelling agent. Examples of suitable crosslinking agents include, but are not limited to, borate ions, zirconium IV ions, titanium IV ions, aluminum ions, antimony ions, chromium ions, iron ions, copper ions, and zinc ions. These ions may be provided by providing any compound that is capable of producing one or more of these ions; examples of such compounds include, but are not limited to, boric acid, disodium octaborate tetrahydrate, sodium diborate, pentaborates, ulexite, colemanite, zirconium lactate, zirconium triethanol amine, zirconium lactate triethanolamine, zirconium carbonate, zirconium acetylacetonate, zirconium malate, zirconium citrate, zirconium diisopropylamine lactate, zirconium glycolate, zirconium triethanol amine glycolate, zirconium lactate glycolate, titanium lactate, titanium malate, titanium citrate, titanium ammonium lactate, titanium triethanolamine, and titanium acetylacetonate, aluminum lactate, aluminum citrate, antimony compounds, chromium compounds, iron compounds, copper compounds, zinc compounds, and combinations thereof. In certain embodiments of the present invention, the crosslinking agent may be formulated to remain inactive until it is “activated” by, among other things, certain conditions in the fluid (e.g., pH, temperature, etc.) and/or contact with some other substance. In some embodiments, the crosslinking agent may be delayed by encapsulation with a coating (e.g., a porous coating) that delays the release of the crosslinking agent until a desired time or place. The choice of a particular crosslinking agent will be governed by several considerations that will be recognized by one skilled in the art, including but not limited to the following: the type of gelling agent included, the molecular weight of the gelling agent(s), the pH of the treatment fluid, temperature, and/or the desired time for the crosslinking agent to crosslink the gelling agent molecules.
When included, suitable crosslinking agents may be present in the treatment fluids of the present invention in an amount sufficient to provide, inter alia, the desired degree of crosslinking between molecules of the gelling agent. In certain embodiments, the crosslinking agent may be present in the treatment fluids of the present invention in an amount in the range of from about 0.0005% to about 0.2% by weight of the treatment fluid. In certain embodiments, the crosslinking agent may be present in the treatment fluids of the present invention in an amount in the range of from about 0.001% to about 0.05% by weight of the treatment fluid. One of ordinary skill in the art, with the benefit of this disclosure, will recognize the appropriate amount of crosslinking agent to include in a treatment fluid of the present invention based on, among other things, the temperature conditions of a particular application, the type of gelling agents used, the molecular weight of the gelling agents, the desired degree of viscosification, and/or the pH of the treatment fluid.
Suitable breakers may include, but not limited to, sodium chlorite, sodium bromate, sodium persulfate, sodium peroxydisulfate, ammonium chlorite, ammonium bromate, ammonium persulfate, ammonium peroxydisulfate, potassium chlorite, potassium bromate, potassium persulfate, potassium peroxydisulfate, one or more oxidizable metal ions (i.e., a metal ion whose oxidation state can be increased by the removal of an electron, such as copper, cobalt, iron, manganese, vanadium), and the like. Examples of such additional breakers are described in U.S. Pat. No. 5,759,964 to Shuchart, et al., and U.S. Pat. No. 5,413,178 to Walker, et al., the relevant disclosures of which are herein incorporated by reference. In certain embodiments of the present invention, the breaker may be formulated to remain inactive until it is “activated” by, among other things, certain conditions in the fluid (e.g., pH, temperature, etc.) and/or contact with some other substance. In some embodiments, the breaker may be delayed by encapsulation with a coating (e.g., a porous coating through which the breaker may diffuse slowly, or a degradable coating that degrades down hole) that delays the release of the breaker until a desired time or place.
The breaker should be present in the treatment fluids in an amount sufficient to provide the desired viscosity reduction. The amount and composition of the breaker utilized in the present invention may depend upon a number of factors, including temperature, the type and/or amount of gelling agents used, the type and/or amount of crosslinking agent used, the pH of the treatment fluid, and the like. One skilled in the art, with the benefit of this disclosure, will recognize the amount and type of breaker suitable for a particular application of the present invention.
The treatment fluids optionally may comprise one or more additional additives known in the art, including, but not limited to, fluid loss control additives, gel stabilizers, gas, salts (e.g., KCl), pH-adjusting agents (e.g., buffers), corrosion inhibitors, dispersants, flocculants, acids, foaming agents, antifoaming agents, H2S scavengers, lubricants, oxygen scavengers, weighting agents, scale inhibitors, surfactants, catalysts, clay control agents, biocides, friction reducers, particulates (e.g., proppant particulates, gravel particulates), combinations thereof, and the like. For example, a gel stabilizer compromising sodium thiosulfate may be included in certain treatment fluids of the present invention. Individuals skilled in the art, with the benefit of this disclosure, will recognize the types of additives that may be suitable for a particular application of the present invention. For example, particulates may be included in the treatment fluids of the present invention in certain types of subterranean operations, including fracturing operations, gravel-packing operations, and the like.
To facilitate a better understanding of the present invention, the following examples of certain aspects of some embodiments are given. In no way should the following examples be read to limit, or define, the entire scope of the invention.
A base fluid was made according to a 30 lbs per 1000 gal of “WG-37” (a xanthan-based gelling agent available from Halliburton Energy Services, in Duncan, Okla.) ratio. The fluid was mixed in a Waring blender. The pH of the fluid was adjusted to 12 by the addition of a base for the crosslinker to be added later. 40 lbs per 1000 gal of 25 micron (median diameter) polylactic acid particles were added for building a filter cake. The following were then added: 2% by volume “WS-44,” which is a surfactant that can be used to disperse the substantially immiscible fluid loss material in the fluid, and 5% by volume “AccuBreak PR,” which is a substantially immiscible delayed acid generator that can improve fluid loss control. Both products are available from Halliburton Energy Services in Duncan Okla. Then, 0.5% by volume “CL-23” crosslinker (available from Halliburton Energy Services in Duncan Okla.) was added. The resultant fluid was allowed to crosslink. A fluid loss test was then performed in a Fann HPHT Cell with 500 psi differential pressure at 180° F. using a 5 micron Aloxit disk. Fluid loss was measured over time.
Therefore, the present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the present invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the present invention. In particular, every range of values (of the form, “from about a to about b,” or, equivalently, “from approximately a to b,” or, equivalently, “from approximately a-b”) disclosed herein is to be understood as referring to the power set (the set of all subsets) of the respective range of values, and set forth every range encompassed within the broader range of values. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee. Thus, the present invention is well adapted to carry out the objects and attain the ends and advantages mentioned as well as those that are inherent therein. While numerous changes may be made by those skilled in the art, such changes are encompassed within the spirit and scope of this invention as defined by the appended claims.
Number | Name | Date | Kind |
---|---|---|---|
2238671 | Woodhouse | Apr 1941 | A |
2703316 | Palmer | Mar 1955 | A |
3173484 | Huitt et al. | Mar 1965 | A |
3195635 | Fast | Jul 1965 | A |
3272650 | MacVittie | Sep 1966 | A |
3302719 | Fischer | Feb 1967 | A |
3364995 | Atkins et al. | Jan 1968 | A |
3366178 | Malone et al. | Jan 1968 | A |
3455390 | Gallus | Jul 1969 | A |
3784585 | Schmitt et al. | Jan 1974 | A |
3819525 | Hattenbrun | Jun 1974 | A |
3828854 | Templeton et al. | Aug 1974 | A |
3836465 | Rhudy et al. | Sep 1974 | A |
3868998 | Lybarger et al. | Mar 1975 | A |
3912692 | Casey et al. | Oct 1975 | A |
3948672 | Harnsberger | Apr 1976 | A |
3955993 | Curtice | May 1976 | A |
3960736 | Free et al. | Jun 1976 | A |
3968840 | Tate | Jul 1976 | A |
3986355 | Klaeger | Oct 1976 | A |
3998272 | Maly | Dec 1976 | A |
3998744 | Arnold et al. | Dec 1976 | A |
4010071 | Colegrove | Mar 1977 | A |
4068718 | Cooke, Jr. et al. | Jan 1978 | A |
4169798 | DeMartino | Oct 1979 | A |
4172066 | Zweigle et al. | Oct 1979 | A |
4261421 | Watanabe | Apr 1981 | A |
4265673 | Pace et al. | May 1981 | A |
4299825 | Lee | Nov 1981 | A |
4387769 | Erbstoesser et al. | Jun 1983 | A |
4460052 | Gockel | Jul 1984 | A |
4470915 | Conway | Sep 1984 | A |
4498995 | Gockel | Feb 1985 | A |
4502540 | Byham | Mar 1985 | A |
4506734 | Nolte | Mar 1985 | A |
4521316 | Sikorski | Jun 1985 | A |
4526695 | Erbstoesser et al. | Jul 1985 | A |
4632876 | Laird et al. | Dec 1986 | A |
4694905 | Armbruster | Sep 1987 | A |
4715967 | Bellis | Dec 1987 | A |
4716964 | Erbstoesser et al. | Jan 1988 | A |
4767706 | Levesque | Aug 1988 | A |
4772346 | Anderson et al. | Sep 1988 | A |
4785884 | Armbruster | Nov 1988 | A |
4793416 | Mitchell | Dec 1988 | A |
4797262 | Dewitz | Jan 1989 | A |
4809783 | Hollenbeck et al. | Mar 1989 | A |
4817721 | Pober | Apr 1989 | A |
4822500 | Dobson, Jr. et al. | Apr 1989 | A |
4829100 | Murphey et al. | May 1989 | A |
4836940 | Alexander | Jun 1989 | A |
4843118 | Lai et al. | Jun 1989 | A |
4848467 | Cantu et al. | Jul 1989 | A |
4863980 | Cowan et al. | Sep 1989 | A |
4886354 | Welch et al. | Dec 1989 | A |
4894231 | Moreau et al. | Jan 1990 | A |
4957165 | Cantu et al. | Sep 1990 | A |
4961466 | Himes et al. | Oct 1990 | A |
4982793 | Holtmyer et al. | Jan 1991 | A |
4986353 | Clark et al. | Jan 1991 | A |
4986354 | Cantu et al. | Jan 1991 | A |
4986355 | Casad et al. | Jan 1991 | A |
5034139 | Reid et al. | Jul 1991 | A |
5067565 | Holtmyer et al. | Nov 1991 | A |
5082056 | Tackett, Jr. | Jan 1992 | A |
5122549 | Holtmyer et al. | Jun 1992 | A |
5142023 | Gruber et al. | Aug 1992 | A |
5152781 | Tang et al. | Oct 1992 | A |
5161615 | Hutchins et al. | Nov 1992 | A |
5203834 | Hutchins et al. | Apr 1993 | A |
5213446 | Dovan | May 1993 | A |
5216050 | Sinclair | Jun 1993 | A |
5247059 | Gruber et al. | Sep 1993 | A |
5249628 | Surjaatmadja | Oct 1993 | A |
5251697 | Shuler | Oct 1993 | A |
5295542 | Cole et al. | Mar 1994 | A |
5304620 | Holtmyer et al. | Apr 1994 | A |
5314031 | Hale et al. | May 1994 | A |
5325923 | Surjaatmadja et al. | Jul 1994 | A |
5330005 | Card et al. | Jul 1994 | A |
5359026 | Gruber | Oct 1994 | A |
5360068 | Sprunt et al. | Nov 1994 | A |
5363916 | Himes et al. | Nov 1994 | A |
5373901 | Norman et al. | Dec 1994 | A |
5386874 | Laramay et al. | Feb 1995 | A |
5396957 | Surjaatmadja et al. | Mar 1995 | A |
5402846 | Jennings, Jr. et al. | Apr 1995 | A |
5413178 | Walker et al. | May 1995 | A |
5439055 | Card et al. | Aug 1995 | A |
5460226 | Lawton et al. | Oct 1995 | A |
5464060 | Hale et al. | Nov 1995 | A |
5475080 | Gruber et al. | Dec 1995 | A |
5484881 | Gruber et al. | Jan 1996 | A |
5487897 | Polson et al. | Jan 1996 | A |
5492177 | Yeh et al. | Feb 1996 | A |
5496557 | Feijen et al. | Mar 1996 | A |
5497830 | Boles et al. | Mar 1996 | A |
5499678 | Surjaatmadja et al. | Mar 1996 | A |
5501276 | Weaver et al. | Mar 1996 | A |
5505787 | Yamaguchi | Apr 1996 | A |
5512071 | Yam et al. | Apr 1996 | A |
5536807 | Gruber et al. | Jul 1996 | A |
5555936 | Pirri et al. | Sep 1996 | A |
5591700 | Harris et al. | Jan 1997 | A |
5594095 | Gruber et al. | Jan 1997 | A |
5602083 | Gabrysch et al. | Feb 1997 | A |
5604186 | Hunt et al. | Feb 1997 | A |
5607905 | Dobson, Jr. et al. | Mar 1997 | A |
5613558 | Dillenbeck | Mar 1997 | A |
5670473 | Scepanski | Sep 1997 | A |
5697440 | Weaver et al. | Dec 1997 | A |
5698322 | Tsai et al. | Dec 1997 | A |
5723416 | Liao | Mar 1998 | A |
5759964 | Shuchart et al. | Jun 1998 | A |
5765642 | Surjaatmadja | Jun 1998 | A |
5783527 | Dobson, Jr. et al. | Jul 1998 | A |
5791415 | Nguyen et al. | Aug 1998 | A |
5799734 | Normal et al. | Sep 1998 | A |
5833000 | Weaver et al. | Nov 1998 | A |
5849401 | El-Afandi et al. | Dec 1998 | A |
5853048 | Weaver et al. | Dec 1998 | A |
5893416 | Read | Apr 1999 | A |
5908073 | Nguyen et al. | Jun 1999 | A |
5916849 | House | Jun 1999 | A |
5924488 | Nguyen et al. | Jul 1999 | A |
5964291 | Bourne et al. | Oct 1999 | A |
5977030 | House | Nov 1999 | A |
5979557 | Card et al. | Nov 1999 | A |
5996693 | Heathman | Dec 1999 | A |
6004400 | Bishop et al. | Dec 1999 | A |
6024170 | McCabe et al. | Feb 2000 | A |
6028113 | Scepanski | Feb 2000 | A |
6047772 | Weaver et al. | Apr 2000 | A |
6110875 | Tjon-Joe-Pin et al. | Aug 2000 | A |
6114410 | Betzold | Sep 2000 | A |
6123159 | Brookey et al. | Sep 2000 | A |
6123965 | Jacob et al. | Sep 2000 | A |
6131661 | Conner et al. | Oct 2000 | A |
6135987 | Tsai et al. | Oct 2000 | A |
6143698 | Murphey et al. | Nov 2000 | A |
6148917 | Brookey et al. | Nov 2000 | A |
6162766 | Muir et al. | Dec 2000 | A |
6169058 | Le et al. | Jan 2001 | B1 |
6172011 | Card et al. | Jan 2001 | B1 |
6189615 | Sydansk | Feb 2001 | B1 |
6202751 | Chatterji et al. | Mar 2001 | B1 |
6209643 | Nguyen et al. | Apr 2001 | B1 |
6209646 | Reddy et al. | Apr 2001 | B1 |
6214773 | Harris et al. | Apr 2001 | B1 |
6242390 | Mitchell et al. | Jun 2001 | B1 |
6260622 | Blok et al. | Jul 2001 | B1 |
6291013 | Gibson et al. | Sep 2001 | B1 |
6300286 | Dobson, Jr. et al. | Oct 2001 | B1 |
6302209 | Thompson et al. | Oct 2001 | B1 |
6308788 | Patel et al. | Oct 2001 | B1 |
6311773 | Todd et al. | Nov 2001 | B1 |
6323307 | Bigg et al. | Nov 2001 | B1 |
6326458 | Gruber et al. | Dec 2001 | B1 |
6328105 | Betzold | Dec 2001 | B1 |
6330917 | Chatterji et al. | Dec 2001 | B2 |
6357527 | Norman et al. | Mar 2002 | B1 |
6364945 | Chatterji et al. | Apr 2002 | B1 |
6380138 | Ischy et al. | Apr 2002 | B1 |
6387986 | Moradi-Araghi et al. | May 2002 | B1 |
6390195 | Nguyen et al. | May 2002 | B1 |
6394185 | Constien | May 2002 | B1 |
6422314 | Todd et al. | Jul 2002 | B1 |
6422326 | Brookey et al. | Jul 2002 | B1 |
6432155 | Swazey et al. | Aug 2002 | B1 |
6454003 | Chang et al. | Sep 2002 | B1 |
6485947 | Rajgarhia et al. | Nov 2002 | B1 |
6488763 | Brothers et al. | Dec 2002 | B2 |
6494263 | Todd | Dec 2002 | B2 |
6508305 | Brannon et al. | Jan 2003 | B1 |
6509301 | Vollmer et al. | Jan 2003 | B1 |
6527051 | Reddy et al. | Mar 2003 | B1 |
6554071 | Reddy et al. | Apr 2003 | B1 |
6566310 | Chan | May 2003 | B2 |
6569814 | Brady et al. | May 2003 | B1 |
6578630 | Simpson et al. | Jun 2003 | B2 |
6599863 | Palmer et al. | Jul 2003 | B1 |
6667279 | Hessert et al. | Dec 2003 | B1 |
6669771 | Tokiwa et al. | Dec 2003 | B2 |
6681856 | Chatterji et al. | Jan 2004 | B1 |
6686328 | Binder | Feb 2004 | B1 |
6691780 | Nguyen et al. | Feb 2004 | B2 |
6702023 | Harris et al. | Mar 2004 | B1 |
6710019 | Sawdon et al. | Mar 2004 | B1 |
6716797 | Brookey | Apr 2004 | B2 |
6737385 | Todd et al. | May 2004 | B2 |
6761218 | Nguyen et al. | Jul 2004 | B2 |
6763888 | Harris et al. | Jul 2004 | B1 |
6764981 | Eoff et al. | Jul 2004 | B1 |
6793018 | Dawson et al. | Sep 2004 | B2 |
6793730 | Reddy et al. | Sep 2004 | B2 |
6806235 | Mueller et al. | Oct 2004 | B1 |
6817414 | Lee | Nov 2004 | B2 |
6818594 | Freeman et al. | Nov 2004 | B1 |
6837309 | Boney et al. | Jan 2005 | B2 |
6883608 | Parlar et al. | Apr 2005 | B2 |
6896058 | Munoz, Jr. et al. | May 2005 | B2 |
6904971 | Brothers et al. | Jun 2005 | B2 |
6949491 | Cooke, Jr. | Sep 2005 | B2 |
6959767 | Horton et al. | Nov 2005 | B2 |
6978838 | Parlar et al. | Dec 2005 | B2 |
6981552 | Reddy et al. | Jan 2006 | B2 |
6983801 | Dawson et al. | Jan 2006 | B2 |
6987083 | Phillippi et al. | Jan 2006 | B2 |
6997259 | Nguyen | Feb 2006 | B2 |
7007752 | Reddy et al. | Mar 2006 | B2 |
7021337 | Markham | Apr 2006 | B2 |
7032663 | Nguyen | Apr 2006 | B2 |
7036586 | Roddy et al. | May 2006 | B2 |
7036587 | Munoz, Jr. et al. | May 2006 | B2 |
7044220 | Nguyen et al. | May 2006 | B2 |
7044224 | Nguyen | May 2006 | B2 |
7063151 | Nguyen et al. | Jun 2006 | B2 |
7066258 | Justus et al. | Jun 2006 | B2 |
7069994 | Cooke, Jr. | Jul 2006 | B2 |
7080688 | Todd et al. | Jul 2006 | B2 |
7093664 | Todd et al. | Aug 2006 | B2 |
7096947 | Todd et al. | Aug 2006 | B2 |
7101829 | Guichard et al. | Sep 2006 | B2 |
7131491 | Blauch et al. | Nov 2006 | B2 |
7140438 | Frost et al. | Nov 2006 | B2 |
7147067 | Getzlaf et al. | Dec 2006 | B2 |
7151077 | Prud'homme et al. | Dec 2006 | B2 |
7156174 | Roddy et al. | Jan 2007 | B2 |
7165617 | Lord et al. | Jan 2007 | B2 |
7168489 | Frost et al. | Jan 2007 | B2 |
7172022 | Reddy et al. | Feb 2007 | B2 |
7178596 | Blauch et al. | Feb 2007 | B2 |
7195068 | Todd | Mar 2007 | B2 |
7204312 | Roddy et al. | Apr 2007 | B2 |
7219731 | Sullivan et al. | May 2007 | B2 |
7228904 | Todd et al. | Jun 2007 | B2 |
7256159 | Guichard et al. | Aug 2007 | B2 |
7261156 | Nguyen et al. | Aug 2007 | B2 |
7264051 | Nguyen et al. | Sep 2007 | B2 |
7267170 | Mang et al. | Sep 2007 | B2 |
7299876 | Lord et al. | Nov 2007 | B2 |
7303014 | Reddy et al. | Dec 2007 | B2 |
7306037 | Nguyen et al. | Dec 2007 | B2 |
7322412 | Badalamenti et al. | Jan 2008 | B2 |
7337839 | Ayoub et al. | Mar 2008 | B2 |
7353876 | Savery et al. | Apr 2008 | B2 |
7353879 | Todd et al. | Apr 2008 | B2 |
7380600 | Willberg et al. | Jun 2008 | B2 |
7413017 | Nguyen et al. | Aug 2008 | B2 |
7448450 | Luke et al. | Nov 2008 | B2 |
7455112 | Moorehead et al. | Nov 2008 | B2 |
7461697 | Todd et al. | Dec 2008 | B2 |
7475728 | Pauls et al. | Jan 2009 | B2 |
7484564 | Welton et al. | Feb 2009 | B2 |
7497258 | Savery et al. | Mar 2009 | B2 |
7497278 | Schriener et al. | Mar 2009 | B2 |
7506689 | Surjaatmadja et al. | Mar 2009 | B2 |
7547665 | Welton et al. | Jun 2009 | B2 |
7595280 | Welton et al. | Sep 2009 | B2 |
7598208 | Todd | Oct 2009 | B2 |
7608566 | Saini et al. | Oct 2009 | B2 |
7608567 | Saini | Oct 2009 | B2 |
20010016562 | Muir et al. | Aug 2001 | A1 |
20020036088 | Todd | Mar 2002 | A1 |
20020119169 | Angel et al. | Aug 2002 | A1 |
20020125012 | Dawson et al. | Sep 2002 | A1 |
20030054962 | England et al. | Mar 2003 | A1 |
20030060374 | Cooke, Jr. | Mar 2003 | A1 |
20030114314 | Ballard et al. | Jun 2003 | A1 |
20030130133 | Vollmer | Jul 2003 | A1 |
20030147965 | Bassett et al. | Aug 2003 | A1 |
20030188766 | Banerjee et al. | Oct 2003 | A1 |
20030230407 | Vijn et al. | Dec 2003 | A1 |
20030234103 | Lee et al. | Dec 2003 | A1 |
20040014606 | Parlar et al. | Jan 2004 | A1 |
20040014607 | Sinclair et al. | Jan 2004 | A1 |
20040040706 | Hossaini et al. | Mar 2004 | A1 |
20040055747 | Lee | Mar 2004 | A1 |
20040070093 | Mathiowitz et al. | Apr 2004 | A1 |
20040094300 | Sullivan et al. | May 2004 | A1 |
20040099416 | Vijn et al. | May 2004 | A1 |
20040106525 | Willberg et al. | Jun 2004 | A1 |
20040138068 | Rimmer et al. | Jul 2004 | A1 |
20040152601 | Still et al. | Aug 2004 | A1 |
20040152602 | Boles | Aug 2004 | A1 |
20040162386 | Altes et al. | Aug 2004 | A1 |
20040170836 | Bond et al. | Sep 2004 | A1 |
20040214724 | Todd et al. | Oct 2004 | A1 |
20040216876 | Lee | Nov 2004 | A1 |
20040231845 | Cooke, Jr. | Nov 2004 | A1 |
20040261993 | Nguyen | Dec 2004 | A1 |
20040261995 | Nguyen et al. | Dec 2004 | A1 |
20040261996 | Munoz, Jr. et al. | Dec 2004 | A1 |
20040261999 | Nguyen | Dec 2004 | A1 |
20050006095 | Justus et al. | Jan 2005 | A1 |
20050028976 | Nguyen | Feb 2005 | A1 |
20050034861 | Saini et al. | Feb 2005 | A1 |
20050034865 | Todd et al. | Feb 2005 | A1 |
20050034868 | Frost et al. | Feb 2005 | A1 |
20050045328 | Frost et al. | Mar 2005 | A1 |
20050051330 | Nguyen | Mar 2005 | A1 |
20050056423 | Todd et al. | Mar 2005 | A1 |
20050059556 | Munoz, Jr. et al. | Mar 2005 | A1 |
20050059557 | Todd et al. | Mar 2005 | A1 |
20050059558 | Blauch et al. | Mar 2005 | A1 |
20050103496 | Todd et al. | May 2005 | A1 |
20050126780 | Todd et al. | Jun 2005 | A1 |
20050126785 | Todd | Jun 2005 | A1 |
20050130848 | Todd et al. | Jun 2005 | A1 |
20050161220 | Todd et al. | Jul 2005 | A1 |
20050167104 | Roddy et al. | Aug 2005 | A1 |
20050167105 | Roddy et al. | Aug 2005 | A1 |
20050167107 | Roddy et al. | Aug 2005 | A1 |
20050183741 | Surjaatmadja et al. | Aug 2005 | A1 |
20050205258 | Reddy et al. | Sep 2005 | A1 |
20050205265 | Todd et al. | Sep 2005 | A1 |
20050205266 | Todd et al. | Sep 2005 | A1 |
20050252659 | Sullivan et al. | Nov 2005 | A1 |
20050272613 | Cooke, Jr. | Dec 2005 | A1 |
20050277554 | Blauch et al. | Dec 2005 | A1 |
20060016596 | Pauls et al. | Jan 2006 | A1 |
20060032633 | Nguyen | Feb 2006 | A1 |
20060046938 | Harris et al. | Mar 2006 | A1 |
20060048938 | Kalman | Mar 2006 | A1 |
20060065397 | Nguyen et al. | Mar 2006 | A1 |
20060105917 | Munoz, Jr. | May 2006 | A1 |
20060105918 | Munoz, Jr. et al. | May 2006 | A1 |
20060108150 | Luke et al. | May 2006 | A1 |
20060169182 | Todd et al. | Aug 2006 | A1 |
20060169448 | Savery et al. | Aug 2006 | A1 |
20060169450 | Mang et al. | Aug 2006 | A1 |
20060169452 | Savery et al. | Aug 2006 | A1 |
20060169453 | Savery et al. | Aug 2006 | A1 |
20060172893 | Todd et al. | Aug 2006 | A1 |
20060172894 | Mang et al. | Aug 2006 | A1 |
20060172895 | Mang et al. | Aug 2006 | A1 |
20060185847 | Saini et al. | Aug 2006 | A1 |
20060185848 | Surjaatmadja et al. | Aug 2006 | A1 |
20060205608 | Todd | Sep 2006 | A1 |
20060234873 | Ballard | Oct 2006 | A1 |
20060243449 | Welton et al. | Nov 2006 | A1 |
20060247135 | Welton et al. | Nov 2006 | A1 |
20060254774 | Saini et al. | Nov 2006 | A1 |
20060258543 | Saini | Nov 2006 | A1 |
20060258544 | Saini | Nov 2006 | A1 |
20060276345 | Todd et al. | Dec 2006 | A1 |
20060283597 | Schriener et al. | Dec 2006 | A1 |
20070042912 | Welton et al. | Feb 2007 | A1 |
20070049501 | Saini et al. | Mar 2007 | A1 |
20070066492 | Funkhouser et al. | Mar 2007 | A1 |
20070066493 | Funkhouser et al. | Mar 2007 | A1 |
20070078063 | Munoz, Jr. | Apr 2007 | A1 |
20070078064 | Munoz et al. | Apr 2007 | A1 |
20070238623 | Saini et al. | Oct 2007 | A1 |
20070281868 | Pauls et al. | Dec 2007 | A1 |
20080026955 | Munoz et al. | Jan 2008 | A1 |
20080026959 | Munoz et al. | Jan 2008 | A1 |
20080026960 | Munoz et al. | Jan 2008 | A1 |
20080027157 | Munoz et al. | Jan 2008 | A1 |
20080070810 | Mang | Mar 2008 | A1 |
20080169102 | Carbajal et al. | Jul 2008 | A1 |
20090062157 | Munoz et al. | Mar 2009 | A1 |
20090258798 | Munoz | Oct 2009 | A1 |
Number | Date | Country |
---|---|---|
0 510 762 | Oct 1992 | EP |
0 879 935 | Nov 1998 | EP |
0 879 935 | Feb 1999 | EP |
1 413 710 | Apr 2004 | EP |
2 412 389 | Mar 2004 | GB |
2004181820 | Jul 2004 | JP |
WO 9315127 | Aug 1993 | WO |
WO 9407949 | Apr 1994 | WO |
WO 9408078 | Apr 1994 | WO |
WO 9408090 | Apr 1994 | WO |
WO 9509879 | Apr 1995 | WO |
WO 9711845 | Apr 1997 | WO |
WO 9927229 | Jun 1999 | WO |
WO 0057022 | Sep 2000 | WO |
WO 0102698 | Jan 2001 | WO |
WO 0187797 | Nov 2001 | WO |
WO 0194744 | Dec 2001 | WO |
WO 0255843 | Jan 2002 | WO |
WO 0212674 | Feb 2002 | WO |
WO 03027431 | Apr 2003 | WO |
WO 03027431 | Apr 2003 | WO |
WO 2004007905 | Jan 2004 | WO |
WO 2004037946 | May 2004 | WO |
WO 2004038176 | May 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20080139415 A1 | Jun 2008 | US |